AK129 + AK117

AK129 + AK117 is a combination of two investigational humanized monoclonal antibodies developed by Akeso. **AK117** (ligufalimab) is an anti-CD47 IgG4 monoclonal antibody designed to block the CD47-SIRPα interaction, enhancing macrophage-mediated phagocytosis of tumor cells and displaying promising safety as it does not induce hemagglutination. AK117 shows antitumor activity in both hematologic malignancies and solid tumors, especially in combination regimens. **AK129** is also a monoclonal antibody being evaluated for cancer therapy; however, specific mechanism details for AK129 are limited in the available literature. The combination is under clinical investigation as part of Akeso’s portfolio, targeting cancer immunotherapy via modulating immune checkpoints and promoting tumor cell clearance[1][2][4].